Active agent encapsulated with a protective composite coating is provided. The coating comprises a first hydrophilic water-swellable inner coating comprising a sealant agent combined with a plasticizer to coat particles of the active agent; and a second hydrophobic outer coating comprising a hydrophobic component combined with an enteric polymer and a plasticizer. The composite coating enhances the stability/viability of the active agent during prolonged storage prior to administration, and on exposure to harsh physiological conditions (e.g. gastric environment) following administration to permit enteric delivery of the active agent. A method of preparing the coated active agent is also provided.

In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.

Provided herein are methods and compositions for oral administration of therapeutic proteins, improved protease inhibitor preparations, methods for producing same, and compositions comprising same.

The present disclosure relates to compositions and methods for treating a subject having a COVID-19 infection. The present disclosure relates to the use of Dichrostachys glomerata extract as a medicament for the treatment of COVID-19 infections.

Oral compositions comprising cinnamaldehyde, and methods or improving circulation and improving circulation by administering such compositions, are described. Methods and uses are describe that include the administration of an effective amount of the oral compositions to improve circulation and increasing nerve sensitization, while also resulting in improved balance, and reduced pain, numbness, and/or tingling in the hands and feet, as well as reduced restlessness, fatigue, and tiredness of the legs.

Provided is a semisolid softgel fill material that includes water and/or other polar solvents, along with a high amount of a nonpolar component, such as an oil. Also provided are methods and systems for producing softgels including the fill material. The softgels produced by the methods and systems provided herein have a normal appearance and retain their structural integrity, even when dried according to conventional methods. Further, when the fill material is added to water or other liquid, as it would be following ingestion, the fill material forms small droplets, thereby enhancing digestion and absorption of the fill material.

In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.

The present invention provides a formulation comprising turmeric extract, which exhibits enhanced aqueous solubility and bioavailability, which is useful for therapeutic applications and overcomes limitations of the prior art. The formulation further comprises at least one of piperine, turmeric oil, acrysol K-140, and bees wax.

Particles comprising a plant protein shell and encapsulating hydrophobic compounds and optionally also bioavailability enhancers, are provided. Further provided is a composition and a kit comprising the particle and methods of preparation thereof. Methods of use, such as for enhancing the bioavailability of the hydrophobic compound, are also provided.

The invention provides a delayed release dosage form and a bolus configured for administration to an animal, wherein said dosage form and said bolus is configured to release a hydrophobic substance to the animal over a period of time. Preferably the hydrophobic substance is a haloform. Also provided is the use of the delayed release dosage form or bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.